# Westlake Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/westlake-therapeutics

- Industry: Biotechnology
- Headquarters: Hangzhou, China
- Website: www.westlaketpx.com
- Total disclosed funding: $15M
- Latest round: Series A (Jun 25, 2022)
- Investors on record: 8

## About

Established in 2020 and based in Hangzhou, China, Westlake Therapeutics (Hangzhou) Co., Ltd., trading as Westlake Therapeutics, is a cell therapy company that focuses on the research and development of blood cell products. he company's team members mainly come from domestic and foreign research institutions, and have accumulated rich technical experience in the field; the company has a 2,800-square-meter R&D center in Hangzhou Yunqi Town, and was recognized as a national high-tech enterprise in 2022. Dr. Xiaofei Gao, the founder of the company, received his PhD from the University of Kansas and completed his postdoctoral research at the Massachusetts Institute of Technology in the United States. In June 2026, Westlake Therapeutics raised over CNY 100 million in venture funding co-led by Taiping Guofa, Real Power Capital, with participation from Efung Capital, Huafang Capital, HSG, and other investors.

The company engages in the research and development of RBC-based cellular medicine. Its product pipeline includes lung cancer, cervical cancer, gout and sepsis, etc. The company's red blood cell engineering platform can produce therapeutically engineered red blood cells derived from human peripheral blood stem cells or adult red blood cells.

The company's revenue is generated by developing and providing next-generation cell therapy.

The latest funds raised in this round will be primarily used to advance the company's pipeline development of red blood cell drug platforms in the fields of oncology and autoimmune diseases, accelerate the clinical validation and registration of core products, and further strengthen the construction of R&D, production and industrialization capabilities.

## Funding rounds

- Series A, Jun 25, 2022, $15M — Efung Capital, Hangzhou Aopeng Investment Management, Hangzhou Xihu District Science and Technology Equity Investment, Westlake University Capital
- Series A, Jul 15, 2021 — Hong Shan, Eight Roads Ventures, CD Capital, Huafang Capital

## Investors

- Hong Shan — Series A
- Eight Roads Ventures (https://capitalatlas.ai/funds/eight-roads-ventures) — Series A
- CD Capital — Series A
- Huafang Capital (https://capitalatlas.ai/funds/huafang-capital) — Series A
- Efung Capital (https://capitalatlas.ai/funds/efung-capital) — Series A
- Hangzhou Aopeng Investment Management (https://capitalatlas.ai/funds/hangzhou-aopeng-investment-management) — Series A
- Hangzhou Xihu District Science and Technology Equity Investment — Series A
- Westlake University Capital — Series A